Posts Tagged ‘MS drugs’

going back.

15Aug16

So… I’m in the process of restarting Rebif. Yeah, I though I’d sworn off injections, too. Gilenya was destroying my immune system… 6? or was it 7? upper respiratory infections this year, and my white cell count was consistently low. I finally said NO MORE earlier this summer… and decided to go drug-free during my […]


i’m here….

03Aug16

I stepped away for a bit. Yeah, you noticed, right? I’ve been busy trying to create a bigger and better fundraiser for this year… switching MS drugs (again)… working a few jobs (still)… planning meaningful travel (as always — that’s what life is about!)… and much more that I can’t wait to tell you about! […]


I’ve been taking Tecfidera for a little more than a week, at a low dose (not the therapeutic dose yet). I switched from Rebif, since I couldn’t tolerate injections any longer. I knew the most common side effects were diarrhea and nausea. While I haven’t really experienced either of those, I’ve been having a lot […]


that was quick.

20Aug14

A few days ago, I was trying to decide between new MS drugs (or, disease-modifying therapies, as we call them, since they only slow progression…) And I did 15 minutes of research to figure it out–or at least to figure out one to try. I think I’ll try Tecfidera (the newest one) first. It’s a […]


I recently returned from another trip to Europe, which, as you may recall from a previous post, is not too challenging for someone with rrMS. I encountered another unexpected snag, and I wanted to let all of you know about it, because I’m going to add something to my future travel routine. Maybe any of […]


You know what stuns me? (aside from, probably, a stun gun. that would probably stun me.) I’ve been trying to find people who do research on the effects of nutrition on MS, aside from the standard potential effects of vitamin D consumption. I’ve had an idea for a Fulbright research proposal (where a faculty member […]


pipeline

17May13

It’s been an exciting past few years in the drug development pipeline for MS (among other diseases). As someone who studied pharmaceutical science in graduate school nearly 20 years ago, as I vaguely follow industry news, I (and others) had thought that new pathways of drug discovery had dried up. Or so the media was […]